[{"from": "human", "value": "What can you tell me about this molecule? [C][N][C][C][C][Branch1][Branch1][C][C][Ring1][=Branch1][C][O][C][=C][Branch2][Ring1][=C][C][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][N][=C][N][=C][Ring1][#Branch1][N][C][=C][Branch1][#Branch2][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][Br][F][O][C]"}, {"from": "gpt", "value": "The molecule is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.  On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients."}]